Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- hepatic transplantation reduces arterial calcification
研究概览
简要总结
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •everyone requiring liver transplantation for the treatment of a chronic liver disease
排除标准
- •MELD score >25, viral replication
研究组 & 干预措施
Patients eligible for Hepatit Transplantation
Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged. HT takes place according to transplant availability. As soon as the patient is able to return home after HT, a visit is organised, defining the T1 period. A visit is carried out 120 days after HT and the end-of-study visit is scheduled to define the T2 period, which is the same length as the T1 period for each patient.
干预措施: a blood test and urine sample collection. (Other)
结局指标
主要结局
hepatic transplantation reduces arterial calcification
时间窗: On the 7th day after surgery
compare the percent of patients with AC progression before and after liver tranplantation
次要结局
- increase of PPi plasma level after liver transplantation(at inclusion and at 3 months)
- identify arterial calcification related factors(On the 7th day after surgery)